Back
CCO Premium Access

CDK4/6 inhibitor ribociclib induces cardiotoxicity through impaired E2F1-regulated spliceosome assembly

Session: Mechanisms of cancer treatment-related cardiovascular toxicity
Topic: Research and New Technology
Speaker: Ms E. Pet (Groningen, NL)
Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

Like

About the speaker

Ms Eva Pet

University Medical Centre Groningen, Groningen (Netherlands (The))
0 follower

4 more presentations in this session

Targeted cardiac inactivation of Guanylate binding protein 5 (GBP5) protects from cardiotoxicity after radiation

Speaker: Doctor M. Heckmann (Heidelberg, DE)

Access
Abstract
Slides
Video
Like
Thumbnail

Cell painting based high-content phenotypic screening to elucidate kinase signaling pathways in ibrutinib-mediated atrial fibrillation

Speaker: Doctor M. Fleming (Nashville, US)

Access
Abstract
Slides
Video
Like
Thumbnail

Mismatch between pre-clinical cardio-oncology and clinical oncology research

Speaker: Mr M. Stabile (Genoa, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Early myocardial metabolic signatures of anthracycline-induced cardiotoxicity

Speaker: Mr C. Galan (Madrid, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Mechanisms of cancer treatment-related cardiovascular toxicity

Speakers: Ms E. Pet, Doctor M. Heckmann, Doctor M. Fleming, Mr M. Stabile, Mr C. Galan
Access
Like
Thumbnail

About the event

Image

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources